2024
Anesthetic Risk with Large Mediastinal Masses: A Management Framework Based on a Systematic Review
Saffarzadeh A, Popescu W, Detterbeck F, Li A, Blasberg J. Anesthetic Risk with Large Mediastinal Masses: A Management Framework Based on a Systematic Review. The Annals Of Thoracic Surgery 2024 PMID: 39307215, DOI: 10.1016/j.athoracsur.2024.09.011.Peer-Reviewed Original ResearchMediastinal massSystematic reviewManagement of patientsVery-high-riskDegree of airwayDegree of symptomsAnatomic compressionRespiratory decompensationRetrospective seriesVascular compressionCase reportAnesthetic managementCategories of low-Anesthetic riskWriting panelIndividual patientsLow riskPubMed databaseDecompensationPatientsHigher-riskPotential decompensationAnesthesiaBack-up planReactive interventionsAssociation of patient socioeconomic status with outcomes after palliative treatment for disseminated cancer
Maduka R, Canavan M, Walters S, Ermer T, Zhan P, Kaminski M, Li A, Pichert M, Salazar M, Prsic E, Boffa D. Association of patient socioeconomic status with outcomes after palliative treatment for disseminated cancer. Cancer Medicine 2024, 13: e7028. PMID: 38711364, PMCID: PMC11074703, DOI: 10.1002/cam4.7028.Peer-Reviewed Original ResearchConceptsOptimal quality of careQuality of carePatient socioeconomic statusAssociated with improved qualityAssociated with improved quality of lifeEnd-of-lifeUS cancer populationPalliative treatmentQuality of lifeCox proportional hazards modelsMultivariate logistic regressionInformed decision makingProportional hazards modelFacility characteristicsNon-HispanicAssociated with lower ratesInsurance payer statusImproving informed decision makingCancer populationSocioeconomic statusHispanic ethnicityTreatment usePayer statusBlack raceLogistic regression
2022
A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation— part 1: a guide to decision-making
Detterbeck FC, Blasberg JD, Woodard GA, Decker RH, Kumbasar U, Park HS, Mase VJ, Bade BC, Li AX, Brandt WS, Madoff DC. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation— part 1: a guide to decision-making. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813719, PMCID: PMC9264102, DOI: 10.21037/jtd-21-1823.Peer-Reviewed Original ResearchLong-term outcomesIndividual patientsHealthy patientsLung cancerFavorable tumorsStage I lung cancerBetter long-term outcomesI lung cancerStage I NSCLCOlder patientsPatient selectionPoint of careSurgical approachClinical careEffect modifiersTreatment selectionPatientsTreatment approachesPatient valuesClinical judgmentSystematic reviewRelevant outcomesLong-term differencesAvailable evidenceShort-term differencesA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 2: systematic review of evidence regarding resection extent in generally healthy patients
Detterbeck FC, Mase VJ, Li AX, Kumbasar U, Bade BC, Park HS, Decker RH, Madoff DC, Woodard GA, Brandt WS, Blasberg JD. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 2: systematic review of evidence regarding resection extent in generally healthy patients. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813747, PMCID: PMC9264068, DOI: 10.21037/jtd-21-1824.Peer-Reviewed Original ResearchNon-randomized comparisonHealthy patientsResection extentIndividual patientsSystematic reviewStage I lung cancerI lung cancerStage I NSCLCCharacteristics of patientsPulmonary function testsLong-term outcomesRisk of recurrenceVideo-assisted approachSublobar resectionWedge resectionRandomized trialsFunction testsLung cancerResidual confoundingEffect modifiersShort-term benefitsLobectomyPatientsPubMed systematic reviewMargin distanceA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 3: systematic review of evidence regarding surgery in compromised patients or specific tumors
Bade BC, Blasberg JD, Mase VJ, Kumbasar U, Li AX, Park HS, Decker RH, Madoff DC, Brandt WS, Woodard GA, Detterbeck FC. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 3: systematic review of evidence regarding surgery in compromised patients or specific tumors. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813753, PMCID: PMC9264070, DOI: 10.21037/jtd-21-1825.Peer-Reviewed Original ResearchLimited pulmonary reserveLong-term outcomesResection extentNon-randomized comparisonPulmonary reserveOlder patientsIndividual patientsFavorable tumorsSystematic reviewStage I lung cancerFavorable long-term outcomeI lung cancerScreen-detected tumorsStage I NSCLCCharacteristics of patientsShort-term outcomesLesser resectionsPerioperative mortalityPulmonary functionSublobar resectionWedge resectionPatient selectionRandomized trialsLung cancerResidual confoundingA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 4: systematic review of evidence involving SBRT and ablation
Park HS, Detterbeck FC, Madoff DC, Bade BC, Kumbasar U, Mase VJ, Li AX, Blasberg JD, Woodard GA, Brandt WS, Decker RH. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 4: systematic review of evidence involving SBRT and ablation. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813762, PMCID: PMC9264060, DOI: 10.21037/jtd-21-1826.Peer-Reviewed Original ResearchLong-term outcomesNon-randomized comparisonIndividual patientsSystematic reviewStage I lung cancerI lung cancerCharacteristics of patientsStage I NSCLCPulmonary function testsMinority of patientsShort-term outcomesStereotactic body radiotherapyThermal ablationLate toxicityPulmonary functionRandomized trialsFunction testsAdjusted comparisonsBody radiotherapyLung cancerResidual confoundingEffect modifiersShort-term benefitsPatientsPubMed systematic review109MO Respect the middle lobe: Perioperative survival of bilobectomy compared to lobectomy and pneumonectomy
Li A, Canavan M, Ermer T, Kaminski M, Maduka R, Zhan P, Flores K, Boffa D, Blasberg J. 109MO Respect the middle lobe: Perioperative survival of bilobectomy compared to lobectomy and pneumonectomy. Annals Of Oncology 2022, 33: s82. DOI: 10.1016/j.annonc.2022.02.136.Peer-Reviewed Original Research
2021
Role of adjuvant therapy in T1-2N0 resected non–small cell lung cancer
Woodard GA, Li A, Boffa DJ. Role of adjuvant therapy in T1-2N0 resected non–small cell lung cancer. Journal Of Thoracic And Cardiovascular Surgery 2021, 163: 1685-1692. PMID: 34334172, DOI: 10.1016/j.jtcvs.2021.05.053.Peer-Reviewed Original ResearchEvolution of the N Descriptor Lymph Node Number vs Lymph Node Location
Blasberg JD, Li A. Evolution of the N Descriptor Lymph Node Number vs Lymph Node Location. CHEST Journal 2021, 159: 2159-2160. PMID: 34099129, DOI: 10.1016/j.chest.2021.01.065.Peer-Reviewed Original ResearchOutcomes of surgically managed primary lung sarcomas: a National Cancer Database analysis
Li AX, Resio BJ, Canavan ME, Papageorge M, Boffa DJ, Blasberg JD. Outcomes of surgically managed primary lung sarcomas: a National Cancer Database analysis. Journal Of Thoracic Disease 2021, 0: 0-0. PMID: 34277037, PMCID: PMC8264694, DOI: 10.21037/jtd-21-1.Peer-Reviewed Original ResearchPrimary lung sarcomaNational Cancer DatabaseLung sarcomaOverall survivalSurgical resectionMultivariable Cox proportional hazards modelsNon-small cell lung cancer patientsNational Cancer Database AnalysisCell lung cancer patientsCox proportional hazards modelCharlson-Deyo scoreFive-year OSMultivariable Cox modelPositive lymph nodesMajority of patientsLung cancer patientsHigh tumor gradeHigh-grade tumorsDifferent histologic subtypesProportional hazards modelAdjuvant chemotherapyParenchymal resectionPulmonary malignancyWorse survivalAdjusted mortalityAdjuvant Chemotherapy for T4 Non-Small Cell Lung Cancer with Additional Ipsilateral Lung Nodules
Li AX, Flores K, Canavan ME, Boffa DJ, Blasberg JD. Adjuvant Chemotherapy for T4 Non-Small Cell Lung Cancer with Additional Ipsilateral Lung Nodules. The Annals Of Thoracic Surgery 2021, 113: 421-428. PMID: 33684345, DOI: 10.1016/j.athoracsur.2021.02.042.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerDifferent ipsilateral lobeCell lung cancerAdditional tumor nodulesT4 non-small cell lung cancerAdjuvant chemotherapyIpsilateral lobeT4 diseaseTumor nodulesLung cancerT4 tumorsOverall survivalSurgical resectionIIIA non-small cell lung cancerAdjuvant multiagent chemotherapyResectable stage IINational Cancer DatabaseFurther prospective studiesLymph node metastasisMultiagent chemotherapyNode metastasisPrimary outcomeProspective studyPatient populationCancer Database